Key result
Carvedilol therapy is an effective adjunctive rate-control therapy in atrial fibrillation and prevents mortality, ventricular arrhythmia, and sudden death in heart failure or post-MI patients.
Why the study?
Does carvedilol reduce mortality and arrhythmias in patients with heart failure or post-myocardial infarction?
Does carvedilol reduce mortality and arrhythmias in patients with heart failure or post-myocardial infarction?
This review highlights carvedilol's efficacy not only in heart failure and post-MI management but also as an effective antiarrhythmic agent for rate control and prevention of ventricular arrhythmias and sudden death.
No takes yet. Share an insight, caveat, or question.
May support adjunctive carvedilol in AF with HF/post-MI; leaves open confirmation by prospective RCTs.
Peter R. Kowey (2005) conducted a review in Heart failure, post-myocardial infarction, atrial fibrillation, ventricular arrhythmias. Carvedilol was evaluated. Carvedilol therapy is an effective adjunctive rate-control therapy in atrial fibrillation and prevents mortality, ventricular arrhythmia, and sudden death in heart failure or post-MI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: